ADHD medications increase dopamine and norepinephrine availability in the prefrontal cortex, improving attention and impulse control. Stimulants (Adderall, Vyvanse, Ritalin) are Schedule II controlled substances and are first-line; non-stimulants (Strattera, Intuniv, Qelbree) take longer to work but have no abuse potential. Vyvanse's prodrug design gives it a smoother profile and lower misuse risk than immediate-release amphetamines. Side effects include appetite suppression, elevated heart rate, and insomnia. All prescribing decisions belong with a qualified clinician.
ADHD Medications Guide: Stimulants vs Non-Stimulants Explained
Attention-deficit/hyperactivity disorder is one of the most commonly diagnosed neurodevelopmental conditions worldwide, affecting an estimated 5–8% of children and 2–5% of adults. The medications used to treat it are simultaneously among the most prescribed and most misunderstood drugs in pharmacy. Adderall, Vyvanse, Ritalin, Strattera — these names appear in news stories about shortages, academic misuse, and psychiatric treatment debates. People prescribed them, parents of children on them, and adults newly diagnosed all benefit from understanding how these drugs actually work.
This guide explains the pharmacology of ADHD medications in plain terms — how stimulants and non-stimulants work differently, what distinguishes Vyvanse from Adderall, what "Schedule II controlled substance" means in practice, and what to expect when starting treatment. Dosing decisions are clinical determinations that belong to your prescriber; this article helps you understand the medication landscape so you can participate more effectively in those conversations.
How ADHD Medications Work: The Neuroscience
ADHD is understood as a disorder of the prefrontal cortex — the region of the brain responsible for executive function, including sustained attention, working memory, impulse control, planning, and emotional regulation. The prefrontal cortex relies heavily on two neurotransmitters, dopamine and norepinephrine, to maintain these functions. In ADHD, the signaling involving these neurotransmitters is dysregulated — levels fluctuate, reuptake is too rapid, or receptor sensitivity is altered — resulting in the characteristic difficulty sustaining attention, regulating impulses, and managing working memory.
All FDA-approved ADHD medications, whether stimulants or non-stimulants, work by increasing the availability of dopamine and norepinephrine in the prefrontal cortex. They differ in how they accomplish this and how quickly. Think of it as turning up the signal-to-noise ratio in a part of the brain that regulates executive function.
The counterintuitive observation that stimulants calm hyperactive children (and help distracted adults focus) confused clinicians for decades. The explanation is that the stimulation is specifically increasing neurotransmitter activity in the prefrontal cortex — the region that normally inhibits impulsive behavior and maintains focused attention. Rather than activating the entire brain non-specifically, ADHD medications at appropriate doses preferentially strengthen the prefrontal control systems that are underactive in ADHD.
Stimulants: Schedule II First-Line Therapy
Stimulants are the first-line pharmacological treatment for ADHD in both children and adults, with the strongest evidence base of any ADHD medication class. They are classified by the DEA as Schedule II controlled substances — the most restrictive category for drugs with accepted medical uses — meaning they have recognized abuse potential and tight prescribing regulations. Despite the schedule classification, decades of research in patients with actual ADHD diagnoses shows appropriate therapeutic use does not cause addiction and may reduce substance use risk compared to untreated ADHD.
Stimulants fall into two primary chemical families: amphetamines and methylphenidates. Both increase dopamine and norepinephrine in the prefrontal cortex, but through different mechanisms, which produces different clinical profiles.
Amphetamines
Mixed amphetamine salts (Adderall, Adderall XR) contain a mixture of amphetamine salt forms. Adderall works by entering presynaptic neurons and triggering active release of dopamine and norepinephrine — it forces the neuron to pump these transmitters out into the synapse. It also inhibits reuptake transporters, preventing the synapse from clearing the neurotransmitters back into the cell. The combined effect is a large increase in synaptic dopamine and norepinephrine. Adderall XR uses a bead delivery system that releases half the beads immediately and half over 4–6 hours, extending the duration to approximately 8–10 hours.
Lisdexamfetamine (Vyvanse) is a prodrug — it is pharmacologically inert as consumed. After absorption, enzymes in red blood cells cleave off an attached lysine amino acid, releasing d-amphetamine (dextroamphetamine), which is the active compound. This enzymatic conversion must occur biologically and cannot be accelerated by taking more medication or by alternative routes of administration — crushing and snorting Vyvanse does not speed up or intensify its effect, unlike immediate-release amphetamine formulations. This design gives Vyvanse a significantly smoother onset and offset, a longer duration of approximately 14 hours, and meaningfully lower abuse potential than other amphetamine formulations. Vyvanse is available in capsule form in multiple strengths.
Dextroamphetamine (Dexedrine) is the pure d-isomer form of amphetamine, available in both immediate-release and spansule (extended-release) formulations. It is one of the oldest ADHD medications still in clinical use.
Methylphenidates
Methylphenidate works differently from amphetamines: rather than forcing active release of dopamine and norepinephrine, it primarily blocks reuptake transporters — the proteins that pull neurotransmitters back from the synapse into the neuron. By blocking reuptake, methylphenidate prolongs the time dopamine and norepinephrine remain available in the synapse. The effect is real but somewhat more modest than amphetamine's dual mechanism of forced release plus reuptake inhibition.
Methylphenidate immediate-release (Ritalin) has a short duration of action — typically 3–5 hours — requiring multiple daily doses. It was the original ADHD stimulant, introduced in the 1950s, and remains in widespread use particularly when fine-grained dose control through the day is clinically useful.
Concerta uses an osmotic pump (OROS) delivery system to release methylphenidate continuously over approximately 10–12 hours, with an initial immediate release followed by ascending levels through the day. This profile reduces afternoon wearing-off and avoids multiple-dose inconvenience.
Dexmethylphenidate (Focalin) is the d-isomer of methylphenidate — the active form. Isolating the active enantiomer allows for a lower total amount of drug to produce equivalent effect. Available in immediate-release and extended-release (Focalin XR) formulations.
Daytrana is a transdermal methylphenidate patch worn on the hip. Its duration of action is controlled by how long the patch is worn (typically 9 hours), and the extended skin depot means effects continue for 2–3 hours after removal. It can be useful for patients with swallowing difficulties or those needing flexible dose duration control.
Stimulant Comparison Table
| Drug (Brand) | Class | Duration | DEA Schedule | Key Feature |
|---|---|---|---|---|
| Mixed amphetamine salts XR (Adderall XR) | Amphetamine | 8–10 hrs | Schedule II | Most widely prescribed amphetamine; IR and XR available |
| Lisdexamfetamine (Vyvanse) | Amphetamine prodrug | ~14 hrs | Schedule II | Longest duration; lower abuse potential via prodrug design |
| Dextroamphetamine (Dexedrine) | Amphetamine | 4–6 hrs (IR) / 6–10 hrs (XR) | Schedule II | Pure d-isomer; one of the oldest ADHD medications |
| Methylphenidate IR (Ritalin) | Methylphenidate | 3–5 hrs | Schedule II | Short-acting; useful for flexible day coverage |
| Methylphenidate ER (Concerta) | Methylphenidate | 10–12 hrs | Schedule II | OROS pump delivery; ascending release profile |
| Dexmethylphenidate ER (Focalin XR) | Methylphenidate (d-isomer) | 8–10 hrs | Schedule II | Active isomer only; may have fewer side effects |
| Methylphenidate patch (Daytrana) | Methylphenidate | Flexible (worn 9 hrs + 2–3 hr tail) | Schedule II | For swallowing difficulties; patch-site skin reactions possible |
Non-Stimulants: Different Mechanism, Different Trade-offs
Non-stimulant ADHD medications do not carry Schedule II classification, have no meaningful abuse potential, and in some cases offer advantages for specific patient profiles. The trade-off is that they generally produce smaller symptom improvements than stimulants on average and — for atomoxetine — require weeks to reach full effect. For patients who cannot tolerate stimulants, have contraindications to them, or need coverage for comorbid conditions, non-stimulants are an important alternative.
Atomoxetine (Strattera)
Atomoxetine is a selective norepinephrine reuptake inhibitor — it blocks the norepinephrine transporter (NET), increasing norepinephrine availability in the prefrontal cortex, which secondarily also increases dopamine in that region (since dopamine reuptake in the PFC is partially handled by the norepinephrine transporter). Unlike stimulants, atomoxetine does not increase dopamine in the nucleus accumbens — the reward circuit — which is why it carries no abuse potential. The clinical downside is the delayed onset: full therapeutic effect typically takes 4–6 weeks to develop, making it impractical for patients who need quick relief and making titration a longer process. Strattera is particularly useful for patients with comorbid anxiety (stimulants can worsen anxiety), a personal or family history of substance use disorders, or patients who have had adverse responses to stimulants. Available in capsule form in multiple strengths.
Guanfacine (Intuniv / Tenex)
Guanfacine is an alpha-2A adrenergic receptor agonist — it activates receptors in the prefrontal cortex that strengthen working memory networks and improve signal transmission in attention circuits. It was originally developed as an antihypertensive (Tenex) and the extended-release formulation (Intuniv) was later approved for ADHD. Guanfacine is particularly effective for hyperactivity, impulsivity, and emotional dysregulation — the behavioral and emotional dimensions of ADHD — in addition to inattention. It is frequently added to stimulant therapy rather than used as a sole agent, providing complementary coverage especially in the evening when stimulants have worn off. It is commonly used in children and adolescents and is less sedating than clonidine.
Clonidine (Kapvay)
Clonidine is also an alpha-2 adrenergic agonist, similar in mechanism to guanfacine but with less receptor selectivity and a more sedating profile. The extended-release formulation (Kapvay) is FDA-approved for ADHD, often used adjunctively with stimulants to address sleep difficulties (a common stimulant side effect), hyperactivity and aggression. The sedation, while a side effect in some contexts, can be therapeutically useful for children whose ADHD symptoms make sleep initiation difficult. Clonidine must not be stopped abruptly — rebound hypertension can occur.
Viloxazine (Qelbree)
Viloxazine is a norepinephrine reuptake inhibitor approved for ADHD in 2021 in children and 2023 for adults — one of the newest non-stimulant options. It was originally developed as an antidepressant in Europe in the 1970s but never achieved broad use there. At ADHD doses, its primary mechanism is norepinephrine reuptake inhibition with some serotonergic activity. It has a faster onset than atomoxetine — clinically meaningful effects can appear within 1–2 weeks — and does not carry Schedule II classification. Available in extended-release capsule form.
Non-Stimulant Comparison Table
| Drug (Brand) | Class | Schedule | Onset of Effect | Best Suited For |
|---|---|---|---|---|
| Atomoxetine (Strattera) | NE reuptake inhibitor | Unscheduled | 4–6 weeks | Comorbid anxiety; substance use history; all-day coverage |
| Guanfacine ER (Intuniv) | Alpha-2A agonist | Unscheduled | 1–4 weeks | Hyperactivity, emotional dysregulation; adjunct to stimulants |
| Clonidine ER (Kapvay) | Alpha-2 agonist | Unscheduled | 1–4 weeks | Sleep difficulties, aggression; adjunct to stimulants; more sedating |
| Viloxazine ER (Qelbree) | NE reuptake inhibitor | Unscheduled | 1–2 weeks | Children & adults; newer option; faster onset than atomoxetine |
Side Effects: What to Anticipate
Appetite Suppression and Weight
Appetite suppression is the most common and consistently reported stimulant side effect, particularly in children. Stimulants suppress appetite during their active window — typically through the lunch hour — and appetite often returns in the evening. Strategies to manage this include eating breakfast before the medication takes effect, offering a larger evening meal, and monitoring growth in children. Long-term effects on height in children have been studied extensively: stimulants may modestly reduce growth velocity in early treatment, but most studies find children largely reach their expected adult height. This is a discussion worth having with your prescriber when initiating treatment in children.
Insomnia
Stimulants increase wakefulness by design, and taking them too late in the day predictably disrupts sleep onset. The solution is usually adjusting the timing of the prescription or switching to a shorter-duration formulation for the afternoon dose — decisions your prescriber makes in concert with you based on your schedule. If evening symptoms require coverage but stimulants disrupt sleep, adjunctive guanfacine or clonidine at bedtime is a common approach.
Elevated Heart Rate and Blood Pressure
Stimulants modestly increase heart rate and blood pressure in most patients — typically within normal clinical ranges but noticeable. In patients with pre-existing cardiovascular conditions, significant hypertension, or structural heart abnormalities, stimulant use requires more careful evaluation and monitoring. Sudden cardiac death in children on stimulants has been studied extensively; current evidence does not support a significant increase in absolute risk for otherwise healthy patients, but the package inserts appropriately note the concern. Cardiac screening questions before starting ADHD medication in children are standard practice.
The Afternoon Comedown
As stimulant levels decline in the afternoon or evening, some patients experience a brief "rebound" period characterized by irritability, emotional sensitivity, and temporary return or worsening of ADHD symptoms. This is distinct from the medication losing effectiveness and instead reflects the transition as drug levels fall. Smoother-onset-and-offset formulations like Vyvanse tend to produce less pronounced rebound than immediate-release preparations. If afternoon rebound is significantly impacting daily life, discuss the pattern with your prescriber — formulation changes can often help.
Potential for Misuse and Diversion
Schedule II stimulants are sought for misuse — primarily by people without ADHD seeking performance enhancement or recreational use. This reality shapes the prescribing environment for patients with genuine ADHD: the regulations designed to prevent diversion create real burdens (monthly appointments, no refills, early refill restrictions) for patients who need reliable medication access. Patients should store their medications securely and be aware that sharing, selling, or giving ADHD medications to others is a federal crime regardless of intent.
DEA Schedule II: What It Means in Practice
All stimulant ADHD medications — amphetamines and methylphenidates — are classified by the DEA as Schedule II controlled substances. Schedule II is defined as drugs with high abuse potential that may lead to severe psychological or physical dependence, but which have accepted medical use. Other Schedule II drugs include opioids like oxycodone and morphine, cocaine (used medically as a topical anesthetic), and fentanyl.
The practical implications for patients are significant:
- No refills permitted: Schedule II prescriptions cannot have refills. A new prescription must be written for every supply period.
- 30-day supply limit: Prescriptions are typically written for a 30-day supply; in many states pharmacies cannot fill them more than a few days early.
- Prescriber visits required: Because no refills are allowed, patients must see their prescriber monthly (or at whatever interval their prescriber writes prescriptions) to obtain their next supply. This creates access challenges for patients in rural areas, those without transportation, or those whose prescribers have limited availability.
- Electronic prescribing of controlled substances (EPCS): Many states now require or prefer electronic prescribing for Schedule II drugs, eliminating paper prescriptions and the associated fraud risk.
- State prescription drug monitoring programs (PDMPs): Every state maintains a database tracking Schedule II prescriptions. Prescribers and pharmacists check these databases to identify concerning patterns of multiple prescribers or pharmacies.
Non-stimulant ADHD medications (Strattera, Intuniv, Kapvay, Qelbree) are not controlled substances. They can be refilled, do not require monthly prescriber visits just for prescription renewal, and are not subject to the same dispensing restrictions. For patients whose ADHD responds adequately to non-stimulants, this represents a meaningful quality-of-life advantage in medication management.
Adults with ADHD: Same Medications, Different Considerations
The same FDA-approved medications are used in adults as in children, though the clinical picture differs in important ways. Adult ADHD frequently presents with more prominent inattentive symptoms than hyperactive-impulsive ones; the bouncing-off-the-walls stereotype more often describes childhood presentation. Adults with ADHD frequently come to diagnosis with decades of compensatory strategies, co-occurring conditions — anxiety and depression are particularly common — and more complex life contexts (job performance, relationships, financial management, parenting) that ADHD affects.
Comorbidity shapes medication selection significantly. An adult with ADHD and significant anxiety may do better starting with atomoxetine or guanfacine rather than stimulants, which can worsen anxiety. An adult with ADHD and major depression might be treated with a medication addressing both conditions, or with sequential treatment. Adults with ADHD and a history of substance use disorders require particularly careful prescribing conversations — non-stimulants or closely monitored stimulant therapy with appropriate safeguards are typical approaches.
Medication Holidays in Children
Some prescribers and families elect to pause stimulant medication during summer breaks, holidays, or weekends — commonly called "drug holidays." The rationale includes allowing growth to catch up (since stimulants may mildly suppress appetite and weight gain during the school year), reducing cumulative cardiovascular exposure, and observing whether ADHD symptoms have naturally improved over time. Critics note that ADHD does not take a summer break — children on medication holidays may struggle socially and behaviorally during those periods. The practice is genuinely controversial within pediatric psychiatry. Whether to use medication breaks, and how to structure them, is a decision that belongs to the prescriber, family, and child — not a general recommendation applicable to all patients.
Frequently Asked Questions
What's the difference between Adderall and Vyvanse?
Both are amphetamine-based, but Vyvanse is a prodrug — pharmacologically inactive until enzymes in the body convert it to d-amphetamine. This conversion cannot be accelerated by taking more or by alternative routes, giving Vyvanse a smoother onset and offset and meaningfully lower abuse potential. Vyvanse also has a longer duration — approximately 14 hours versus Adderall XR's 8–10 hours. Adderall offers both immediate-release and extended-release formulations, giving more flexibility in structuring coverage through the day. Your prescriber selects the appropriate medication based on your clinical situation, response to previous treatments, and individual factors.
Can ADHD medications cause addiction?
When used as prescribed by a person with a genuine ADHD diagnosis, research consistently finds that stimulant treatment does not cause addiction and may actually reduce the risk of later substance use compared to untreated ADHD. The brain of someone with ADHD responds differently to therapeutic stimulant doses than someone without ADHD — it normalizes dysregulated neurotransmitter function rather than producing the reward surge that drives compulsive use. Misuse (taking more than prescribed, using without a diagnosis, or using by alternative routes) does carry real addiction risk. If you have concerns about your medication use or notice troubling patterns, speak openly with your prescriber.
Why does my ADHD medication wear off in the afternoon?
Extended-release ADHD medications have a finite duration by design. As blood levels decline, the pharmacological effect diminishes — this is intended. What some patients experience as a "rebound" is the contrast between the medicated and unmedicated state; symptoms may feel worse than baseline briefly before returning to their normal untreated level. Solutions include adjusting dose timing, switching to a longer-duration formulation like Vyvanse, or adding a small afternoon dose under your prescriber's direction. This is a common, solvable problem — bring it up specifically at your next appointment.
Are non-stimulants as effective as stimulants?
On a population level, stimulants produce larger reductions in core ADHD symptoms than non-stimulants — this is consistent across research. However, many patients respond well to non-stimulants, and for patients who cannot tolerate stimulants (due to anxiety, cardiovascular concerns, or adverse effects) or have contraindications, non-stimulants are effective and appropriate options. Guanfacine and clonidine specifically target behavioral dimensions (hyperactivity, impulsivity, emotional dysregulation) where they can be comparable or superior to stimulants. Individual response varies enormously — population-level statistics do not predict your personal response.
Can adults be diagnosed with ADHD?
Yes — ADHD is a neurodevelopmental condition that persists into adulthood in the majority of cases diagnosed in childhood, and many adults were never diagnosed in childhood despite meeting criteria. Adult ADHD diagnosis requires evidence that symptoms were present before age 12, persist across settings, and cause meaningful functional impairment. Women and girls were historically underdiagnosed because the inattentive presentation (more common in females) was missed in an era focused on hyperactive boys. Evaluation involves a thorough clinical assessment — speak with a qualified psychiatrist, psychologist, or specially trained primary care provider if you believe this applies to you.
Identify a pill by imprint, shape, and color — or check interactions between your ADHD medications and other prescriptions.
Check Drug Interactions